2026 Annual Meeting
Log in
Language
Resource center
Contact app support
Legal
Home
Speakers
Register for AUA2026
Agenda
Navigate the Meeting - Floor Plan
AUA TV
Attendee Survival Guide for Trainees
IP38: Prostate Cancer: Advanced (including drug therapy) I
Saturday, May 16, 2026 1:00 PM to 3:00 PM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Prostate
Saturday, May 16
IP38-01: Tipifarnib Suppresses Exosome Biogenesis/Secretion in Aggressive Prostate Cancer Cells: Working Toward an Adjuvant Strategy to Overcome Enzalutamide Resistance
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-02: Neoadjuvant apalutamide therapy enhances potency preservation following radical prostatectomy by downstaging the disease in men with high-risk prostate cancer: results of a randomized three-arm phase II trial
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-03: Pathologic Responses with Intensified Neoadjuvant Therapy Approaches Prior to Radical Prostatectomy: A Systematic Review and Meta-Analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-04: Comparison of EMBARK and EAU Criteria to Identify High-Risk Patients with Biochemical Recurrence After Radical Prostatectomy
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-05: Development and clinical implementation of a simple radium-223 non-completion risk calculator for bone-metastatic castration-resistant prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-06: Clinical Investigation of Docetaxel Therapy for Castration-Resistant Prostate Cancer in Patients Aged 75 Years or Older
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-07: Nationwide genomic data analysis of Japanese advanced prostate cancer ~analyzing C-CAT database~
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-08: Redefining Multimodal Treatment in High-volume metastatic hormone-sensitive prostate cancer: Prospective Evidence for Robot-assisted Cytoreductive Prostatectomy Following Triplet Systemic Therapy
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
Lixin Hua
IP38-09: Subtypes and Treatment Strategies of non-pCR High-Risk /Locally Advanced Prostate Cancer Post-Neoadjuvant Hormonal Therapy
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
Yi Cai · Xiangya Hospital, Central South University
IP38-10: Referral from urology to oncology practices for patients (pts) with metastatic prostate cancer (mPC) in the real world: a PRostatE Cancer dISease observatION (PRECISION) data platform analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-11: Development and validation of a prognostic model to guide the optimal timing of Docetaxel after an Androgen Receptor Pathway Inhibitor in mCRPC
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-12: Uptake of doublet and triplet therapy for men with de novo metastatic castration sensitive prostate cancer. Population-based study
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-13: Does Triplet Therapy Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer? A Bayesian Individual Patient Data Reanalysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-14: Dissecting Synergistic vs. Additive Contributions to Survival in the ARASENS Triplet Regimen: A Modeling Analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-15: Real-World Treatment Sequence and Completion Outcomes of Radium-223 With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-16: First-in-humanstudy of Prostate-Specific Membrane Antigen(PSMA)-targeted chimeric antigen receptor engineered natural killer cells(CAR-NK) for Metastatic Castration Resistant Prostate Cancer(mCRPC)
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
Kehao Pan
IP38-17: Implementation of a Multidisciplinary Quality Initiative to Mitigate and Reduce the Side Effects of Androgen Deprivation Therapy (ADT) in Prostate Cancer Patients Based on the Prostate Cancer 360 (PC360) Working Group Recommendations
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-18: Interplay between prostate cancer treatment and diabetes: a retrospective cross-sectional study in Veterans with metastatic prostate cancer and type 2 diabetes
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-19: Association between serum testosterone levels and de novo volume of bone metastases in patients with metastatic castration-sensitive prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-20: Temporal changes in prostate-specific antigen doubling time and their predictive value for second novel androgen receptor signaling inhibitor response in non-metastatic castration-resistant prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-21: Testosterone suppression and recovery in patients with advanced prostate cancer treated with relugolix: an interim analysis of the OPTYX study
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-22: Testosterone Recovery After Cessation of Androgen Deprivation Therapy for Prostate Cancer: An Updated Single-Arm Meta-analysis of Prospective Trials
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-23: GLP-1 RECEPTOR AGONISTS REDUCE MORTALITY AND HOSPITALIZATION IN DIABETIC PATIENTS WITH UROLOGIC MALIGNANCIES: A RETROSPECTIVE COHORT STUDY
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-24: SGLT2i vs DPP-4i in Prostate Cancer Patients on Androgen Deprivation Therapy with Type 2 Diabetes Mellitus: A Propensity-Matched TriNetX Analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-25: Association Between Metabolic Syndrome and Treatment Outcomes in Metastatic Prostate Cancer: A Retrospective Cohort Analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-26: Exploratory phase of the SPoRT-MU trial: impact of velocity-based resistance training on Patient-Reported Outcomes in advanced prostate cancer.
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-27: Discordance between PSA level and bone-metastatic volume is associated with unfavorable prognosis in patients with metastatic hormone-sensitive prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
IP38-28: Patient Perspectives on Orchiectomy vs Hormone Therapy in Advanced Prostate Cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
Darryl Mitteldorf · Malecare Cancer Support
IP38-30: Bayesian Reanalysis of Olaparib Efficacy in the Asian Subgroup of the PROfound Trial
Saturday, May 16, 2026 1:00 PM to 3:00 PM
146A
Registered attendees
KS
Kristian Stensland
Assistant Professor
University of Michigan
Petra Popovics
Assistant Professor
Eastern Virginia Medical School at Old Dominion University
Log in
See all the content and easy-to-use features by logging in or registering!
Log in
Continue as a guest
